

01/22/02  
JC698 U.S. PTO

Please type a sign (+) inside this box

PTO/SB/05 (08-00)

Approved for use through 10/31/2002 OMB 0651-00  
Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE  
1005186 PRO 01/22/02

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**UTILITY  
PATENT APPLICATION  
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

**APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility patent application contents

1.  Fee Transmittal Form (e.g., PTO/SB/17) (in duplicate)  
(Submit an original, and a duplicate for fee processing)
2.  Applicant claims small entity status.  
See 37 CFR 1.27.
3.  Specification [Total Pages 56]  
(preferred arrangement set forth below)
  - Descriptive title of the invention
  - Cross Reference to Related Applications
  - Statement Regarding Fed sponsored R & D
  - Reference to sequence listing, a table, or a computer program listing appendix
  - Background of the invention
  - Brief Summary of the invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
4.  Drawing(s) (35 U.S.C. 113) [Total Sheets 11]
5.  Declaration [Total Pages 2]
  - a.  Newly executed (original or copy)
  - b.  Copy from a prior application (37 CFR 1.63(d))  
(for continuation/divisional with Box 17 completed)
  1.  **DELETION OF INVENTOR(S)**  
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
6.  Application Data Sheet. See 37 CFR 1.76. (5 pages)

Attorney Docket No.	PF129C2
First Inventor	Adamou et al.
Title	Calcitonin Gene Related Peptide Receptor
Express Mail Label No.	

**ADDRESS TO:**  
Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

7.  CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission  
(if applicable, all necessary)
  - a.  Computer Readable Form (CRF)
  - b. Specification Sequence Listing on:
    - i.  CD-ROM or CD-R (2 copies); or
    - ii.  paper
  - c.  Statement(s) verifying identity of above copy

**ACCOMPANYING APPLICATION PARTS**

9.  Assignment Papers (cover sheet and document(s))
10.  37 CFR 3.73(b) Statement  Power of Attorney
11.  English Translation Document (if applicable)
12.  Information Disclosure Statement/ Form PTO/SB/08
  - Copies of Citations
13.  Preliminary Amendment and Version With Markings to Show Changes Made
14.  Return Receipt Postcard (MPEP 503)  
(should be specifically itemized)
15.  Certified copy of Priority Document(s)  
(if foreign priority is claimed)
16.  Other:
  - a. Request Under 37 CFR § 1.821(e)(1) pg.)
  - b. Substitute Sequence Listing (9 pages)
  - c. Copies of three (3) Notice of Recordations and three (3) Assignments (10 pages)

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76

Continuation  Divisional  Continuation-in-Part (CIP) of prior application No: 09/455,442, filed December 6, 1999

Prior application information: Examiner \_\_\_\_\_

Group/Art Unit: \_\_\_\_\_

For CONTINUATION OR DIVISIONAL APPS only. The entire disclosure of the prior application from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts

**18. CORRESPONDENCE ADDRESS**

Customer Number or Bar Code Label 22195 or  Correspondence address below

NAME				
ADDRESS				
CITY	STATE	ZIP CODE		
COUNTRY	TELEPHONE	FAX		
NAME (Print/Type)	Registration No. (Attorney/Agent)		41,119	
SIGNATURE	Date <u>1/22/02</u>			

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

20/22/10  
JCC 8698  
PTO

# FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

Total amount of payment

**\$740.00**

*Complete if Known*

Application Number	Unassigned
Filing Date	Herewith
First Named Inventor	Adamou et al.
Examiner Name	Unassigned
Group Art Unit	Unassigned

Attorney Docket Number

**PF129C2**

## METHOD OF PAYMENT

1.  The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to.

Deposit Account Number **08-3425**

Deposit Account Name **Human Genome Sciences, Inc.**

Charge Any Additional Fee Required  
Under 37 CFR §§ 1.16 and 1.17

Applicant claims small entity status  
See 37 CFR 1.27

2.  Payment Enclosed:  
 Check  Credit Card  Money Order  Other\*

## FEE CALCULATION

### 1. BASIC FILING FEE

Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
101	740	201	370	Utility filing fee			740
106	330	206	165	Design filing fee			
107	510	207	255	Plant filing fee			
108	740	208	370	Reissue filing fee			
114	160	214	80	Provisional filing fee			

**SUBTOTAL (1)** **\$740.00**

### 2. EXTRA CLAIM FEES

Total Claims	20	-20**	Extra Claims	Fee from below	Fee Paid
Independent Claims	2	-3**		\$84.00	
Multiple Dependent				\$280.00	

### Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	
103	18	203	9	Claims in excess of 20
102	84	202	42	Independent claims in excess of 3
104	280	204	140	Multiple dependent claim, if not paid
108	84	209	42	** Reissue independent claims over original patent
110	18	210	9	** Reissue claims in excess of 20 and over original patent

**SUBTOTAL (2)** **\$740.00**

\*\* or number previously paid, if greater; For Reissues, see above

### 3. ADDITIONAL FEES

Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Description	Fee Paid
105	130	205	65	Surcharge - late filing fee or oath	
127	50	227	25	Surcharge - late provisional filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for <i>ex parte</i> reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	400	216	200	Extension for reply within second month	
117	920	217	460	Extension for reply within third month	
118	1,440	218	720	Extension for reply within fourth month	
128	1,960	228	980	Extension for reply within fifth month	
119	320	219	160	Notice of appeal	
120	320	220	160	Filing a brief in support of an appeal	
121	280	221	140	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use hearing	
140	110	240	55	Petition to revive - unavoidable	
141	1,280	241	640	Petition to revive - unintentional	
142	1,280	242	640	Utility issue fee (or reissue)	
143	460	243	230	Design issue fee	
144	620	244	310	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Processing fee under 37 CFR 1.17(q)	
126	180	126	180	Submission of Information Disclosure Statement	
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	740	246	370	Filing a submission after final rejection (37 CFR § 1.129(a))	
149	740	249	370	For each additional invention to be examined (37 CFR § 1.129(b))	
179	740	279	370	Request for Continued Examination (RCE)	
169	900	169	900	Request for expedited examination of a design application	
145	100	145	100	Certificate of correction	
148	110	248	55	Statutory disclaimer	
561	3	561	3	Printed copy of patent, regular service	

Other fee (specify):

Other fee (specify):


\* Reduced by Basic Filing Fee Paid

**SUBTOTAL (3)**

**\$0.00**

## Submitted By

Complete (if applicable)

Name (Print/Type) Jonathan L. Klein	Registration No.: 41,119	Telephone (301) 251-6015
Signature: 		Date: 1/22/02

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Adamou et al.

Application Serial No.: To Be Assigned

Art Unit: To Be Assigned

Filed: Concurrently Herewith

Examiner: To Be Assigned

For: Calcitonin Gene Related Peptide Receptor

Atty. Docket: **PF129C2**

**REQUEST UNDER 37 C.F.R. § 1.821(e)**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

The above-identified patent application is a continuation of application Serial No. 09/455,442, filed December 6, 1999. The substitute sequence listing of the instant application is identical to the sequence content of the computer readable sequence listing filed on May 11, 2001 in connection with Application Serial No. 09/455,442.

In accordance with 37 C.F.R. § 1.821(e), please use the computer readable form last-filed in connection with application Serial No. 09/455,442 as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the original and Substitute Sequence Listing is included in the specification of the instant application filed herewith. Applicants hereby certify that the paper copy of the Substitute Sequence Listing filed herewith and the computer readable sequence listing last-filed in connection with application Serial No. 09/455,442 are the same and do not include new matter.

Respectfully submitted,

Dated: 1/22/02

  
Jonathan L. Klein (Reg. No. 41,119)  
Attorney for Applicants

**Human Genome Sciences, Inc.**  
9410 Key West Avenue  
Rockville, MD 20850  
Telephone: (301) 251-6015

JLK/DAS/mbp